Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors
- 1 March 2006
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (3) , 678-679
- https://doi.org/10.1111/j.1538-7836.2006.01829.x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Delayed tirofiban‐induced thrombocytopenia: two case reportsJournal of Thrombosis and Haemostasis, 2005
- Eptifibatide-Associated Acute, Profound ThrombocytopeniaAnnals of Pharmacotherapy, 2005
- Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa InhibitorsChest, 2005
- Thrombocytopenia Resulting from Sensitivity to GPIIb-IIIa InhibitorsSeminars in Thrombosis and Hemostasis, 2004
- Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drugJournal of Thrombosis and Haemostasis, 2004
- Final results of the ReoPro readministration registryThe American Journal of Cardiology, 2004
- Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotensionCatheterization and Cardiovascular Interventions, 2002
- Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIaBlood, 2002
- Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediatedBlood, 2002
- Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularizationJournal of the American College of Cardiology, 1998